ClinicalTrials.gg
RecruitingNCT07584330COMET-AIUpdated Oct 27, 2026

AI-Driven Metabolic Cohort in Overweight/Obese Chinese Adults

An observational study in Overweight and Obesity, Diabetes Mellitus, Type 2 and Prediabetic State, sponsored by Zhujiang Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Zhujiang Hospital · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 27, 2026Now RecruitingFirst site in China+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,800
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 603 studies in Obesity with a site in China — 223 open to participants now, 284 under way, 67 of them phase 3. Obesity · China.

Planned enrollment
29th of 99
2,800 · median 320
Started
2026
with 135 others
Observational
99 of 603
37 open now
Primary completion
2032-04
later than 276 of 282 live
Registered
503rd of 603
by date

Among the 603 studies in Obesity with a site in China, this one is the 29th largest by planned enrollment of the 99 observational ones that give a count, is one of 136 that started in 2026, is one of 99 observational ones, reaches primary completion later than 276 of the 282 other live ones, and was the 503rd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

223 of the 603 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

218 more — sign in →

All 223 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 603 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

The goal of this observational cohort study is to delineate the five-year dynamic trajectories of metabolic phenotypes in Chinese adults with overweight or obesity, with or without type 2 diabetes, focusing on transition rates from metabolically healthy overweight/obesity to unhealthy overweight/obesity or to type 2 diabetes, as well as the incidence and progression of diabetic complications and cardiovascular events in those with type 2 diabetes and overweight/obesity. Researchers will compare three phenotype groups, namely metabolically healthy overweight/obesity, metabolically unhealthy overweight/obesity, and type 2 diabetes with overweight/obesity, to assess differences in metabolic parameter changes, complication rates, and cardiovascular risk. Participants will use a digital health management platform for data upload and lifestyle support, and will complete comprehensive health assessments at baseline, at 2.5 years, and at 5 years, along with annual light follow-ups.

03

Conditions studied

  • Overweight and Obesity
  • Diabetes Mellitus, Type 2
  • Prediabetic State
  • Metabolic Syndrome

Keywords

  • Overweight and Obesity
  • Type 2 Diabetes Mellitus
  • Metabolic Syndrome
  • Metabolic Phenotype
  • Prospective Study
  • Cohort Study
04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 2,800 is above the median of 115 across 2,159 observational studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Zhujiang Hospital is the lead sponsor of 202 studies on the registry; 96 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Chinese adults aged 18-60 years with overweight or obesity (BMI ≥ 24 kg/m² or central obesity: male waist circumference ≥ 90 cm, female ≥ 85 cm). Enrolled from 24 hospitals across China. Participants are classified into three groups: metabolically healthy overweight/obesity (MH-OW/OB), metabolically unhealthy overweight/obesity (MU-OW/OB), and type 2 diabetes with overweight/obesity (T2DM-OW/OB). All participants must be able to use a smartphone for daily communication and provide written informed consent. Key exclusions include type 1 diabetes, severe hepatic/renal impairment, uncontrolled hypertension or diabetes (HbA1c > 9.0%), active malignancy, pregnancy, and conditions interfering with follow-up or AI platform use.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and voluntarily sign the form, and willing to comply with all study requirements.
  2. Age between 18 and 60 years (inclusive).
  3. Meets at least one of the following overweight/obesity criteria: a) ≥ 24 kg/m²; b) male waist circumference ≥ 90 cm, female waist circumference ≥ 85 cm.
  4. Capable of basic smartphone operation and able to use WeChat or similar communication tools for daily communication.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of type 1 diabetes, latent diabetes in adults (LADA), maturity-onset diabetes of the young (MODY), or other specific types of diabetes.
  2. Endocrine or metabolic diseases that may affect body weight, including untreated thyroid disorders (hyperthyroidism: TSH \< 0.1 mIU/L with FT4 > upper normal limit; hypothyroidism: TSH > 10 mIU/L), Cushing syndrome, acromegaly, polycystic ovary syndrome, or hypopituitarism.
  3. Severe liver disease ( class B or C).
  4. Renal insufficiency (estimated \< 30 mL/min/1.73 m²).
  5. Severe cardiac dysfunction ( class III or IV).
  6. Major cardiovascular or cerebrovascular event within the past 3 months (acute coronary syndrome, stroke).
  7. Uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg or diastolic ≥ 110 mmHg) or uncontrolled diabetes ( ≥ 9.0%).
  8. Active (diagnosed or treated within the last 3 years).
  9. Inflammatory bowel disease or conditions causing malabsorption (Crohn disease, active ulcerative colitis, pancreatitis with steatorrhea).
  10. Neuropsychiatric disorders (anorexia nervosa, bulimia nervosa, schizophrenia, major depression, or bipolar disorder).
  11. Diseases or physical conditions that impair motor function (severe osteoarthritis, Parkinson disease, paralysis, or cardiopulmonary insufficiency).
  12. Long-term use of antipsychotic drugs, systemic , or other medications judged by the investigator to affect study outcomes.
  13. Pregnancy or planned pregnancy during the study period.
  14. History of or planned organ transplantation.
  15. Inability to operate the AI-based system or comply with follow-up procedures.
  16. Concurrent participation in another interventional clinical trial that may influence the results of this study.
  17. Unwilling or unable to provide .
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,800 participants (estimated)
Patient registry
No

Groups and cohorts

  • MH-OW/OB

    Participants with overweight or obesity without diabetes; HbA1c \< 5.7% and fasting glucose \< 5.6 mmol/L; no metabolic abnormalities (blood pressure \<130/85 mmHg or no antihypertensives; triglycerides \<1.7 mmol/L or no lipid-lowering drugs; HDL-C ≥1.0 mmol/L for men or ≥1.3 mmol/L for women).

  • MU-OW/OB

    Participants with overweight or obesity without diabetes; HbA1c \< 6.5% and fasting glucose \< 7.0 mmol/L; at least one metabolic abnormality (blood pressure ≥130/85 mmHg or on antihypertensives; triglycerides ≥1.7 mmol/L or on lipid-lowering drugs; HDL-C \<1.0 mmol/L for men or \<1.3 mmol/L for women; or fasting glucose 5.6-6.9 mmol/L).

  • T2DM-OW/OB

    Participants with overweight or obesity with established type 2 diabetes (fasting glucose ≥7.0 mmol/L, 2h-post-OGTT glucose ≥11.1 mmol/L, HbA1c ≥6.5%, or random glucose ≥11.1 mmol/L with typical symptoms); stable antidiabetic treatment for ≥3 months; screening HbA1c ≤ 9.0%.

07

What researchers measure

Primary outcomes

  1. Phenotype Transition Rate

    Conversion from metabolically healthy overweight/obesity (MH-OW/OB) to metabolically unhealthy overweight/obesity (MU-OW/OB) or to type 2 diabetes with overweight/obesity (T2DM-OW/OB); including transition rate and time to transition.

    Time frame: Baseline, 2.5 years, 5 years

  2. Complications in T2DM-OW/OB Group

    Incidence of new-onset diabetic complications (nephropathy, retinopathy, neuropathy) and progression of pre-existing complications in participants with type 2 diabetes and overweight/obesity.

    Time frame: Baseline, 2.5 years, 5 years

Secondary outcomes

  1. Longitudinal Changes in Metabolic Parameters

    Absolute change and annual rate of change from baseline to 2.5 and 5 years for weight, BMI, waist circumference, hip circumference, waist-to-hip ratio, waist-to-height ratio, body fat mass, body fat percentage, muscle mass, visceral fat area, fasting glucose, fasting insulin, fasting C-peptide, HOMA-IR, HbA1c, total cholesterol, triglycerides, HDL-C, LDL-C, ALT, AST, creatinine, urea, uric acid.

    Time frame: Baseline, 2.5 years, 5 years

  2. Diabetic Microvascular Complications

    Incidence and progression of diabetic nephropathy and diabetic retinopathy. (Diabetic neuropathy is also assessed but not included as a formal outcome for this measure.)

    Time frame: Baseline, 2.5 years, 5 years

  3. Major Adverse Cardiovascular Events

    Time to first occurrence of myocardial infarction, stroke, coronary revascularization, or cardiovascular death.

    Time frame: Baseline, 2.5 years, 5 years

  4. All-Cause Mortality

    Death from any cause.

    Time frame: Baseline, 2.5 years, 5 years

  5. Cardiovascular Risk Comparison Across Phenotypes

    Cumulative incidence and hazard ratio of cardiovascular events (myocardial infarction, stroke, revascularization) among the three phenotype groups (MH-OW/OB, MU-OW/OB, T2DM-OW/OB) over 5 years of follow-up.

    Time frame: Baseline, 2.5 years, 5 years

08

Study locations

1 of 1 sites recruiting
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Apr 2032, 69 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 69 months is above that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

Start moved once since we started tracking on Sep 25, 2026: May 2026 → Jul 2026, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 13, 2026
StartActual
Jul 1, 2026was May 2026
Primary completionEst.
Apr 1, 2032
CompletionEst.
Apr 1, 2032
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
1 site added — first site in China
Show site
  • Zhujiang Hospital · Guangzhou, China
Oct 27, 2026
Start date
May 1, 2026→Jul 1, 2026 (actual)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Zhujiang Hospital · Guangzhou, China
    Start date May 1, 2026→Jul 1, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07584330
Lead sponsor
Zhujiang Hospital
Responsible party
Sponsor
First posted
May 13, 2026
Start date
Jul 1, 2026
Primary completion
Apr 1, 2032 (estimated)
Completion
Apr 1, 2032 (estimated)
Last update
Oct 27, 2026

Study contacts

Hong Chen, Ph.D.
Contact
rubychfq@163.com
+86 20 61643888

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion